Future Technology Trends

The strategies for engineered negligible senescence program is searching for novel methods to overcome the aging process. While medical technology has progressed an astounding amount over the last 100 years, lifespans have not increased as much as many previously had hoped. One apparent target for longevity medicine is to get rid of extracellular junk that may cause various biological breakdowns as someone gets older. AmyloSENS is the name of this undertaking. The goal is to remove amyloid plaques that begin to accumulate within the body. The heart receives damage due to these products over the course of decades. This can lead to coronary issues later in life. The proteins that may aggregate in the region include senile systemic amyloidosis (SSA), isolated atrial amyloidosis (IAA) and “cardiac amyloidoses”. Alzheimer’s disease, for instance, is also associated with too much of a specific substance. Destruction of neurons in key areas involved with memory possibly happens because of these things. Stopping this process early could potentially help maintain a person’s normal cognition. 

This is an interesting strategy, but as a route for anti-aging it may be less than ideal. Discovering novel antibodies that can break up this junk is certainly plausible. However, a person would likely need to take many different therapies for a lengthy period in order to extend their lifespan. Most people are not Ray Kurzweil and might be unwilling to do such a drastic regimen. There is no telling how many side effects someone would have to deal with when chasing after so many targets. For big pharma, there tends to be a lot of early hype for new techniques. Unfortunately, after numerous failures, the reality sets in that it difficult to obtain FDA approval for stuff. There are so many other parts of the body that would need to be ameliorated as well. This would probably be too expensive for most people. You might have to spend a ton of money, but have little appreciable gain in healthy years. It seems easy to discount the concept of extreme longevity as effectively dead in the water for the immediate future. The anti-aging field is full of many snake-oil salesmen who think that taking the right balance of compounds will help reprogram their biology. SENS is more respectable than many other ventures, but it may fall short. Even sophisticated bio-machines might be a long way off and would be hampered by what they could do. Cost and approval factors may still come into consideration before those tailored cells could find their way into the hospital setting.